AVI posts positive results in Hepatitis C study

AVI BioPharma says the first stage of its trial of a new Hepatitis C therapy has been completed with good results. Researchers tested Neugene on 30 patients at three different dose levels without posting any serious side effects. A new stage will test higher doses of the drug on 40 patients. AVI's stock ticked up on the news.

- for more information, read this AP report

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.